These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 35203791)
41. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents. Bader MS; Loeb M; Leto D; Brooks AA Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743 [TBL] [Abstract][Full Text] [Related]
42. In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014-2018 studies in Italy. Stracquadanio S; Torti E; Longshaw C; Henriksen AS; Stefani S J Glob Antimicrob Resist; 2021 Jun; 25():390-398. PubMed ID: 34020073 [TBL] [Abstract][Full Text] [Related]
44. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]
45. High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane region, South Africa - an update. Lowings M; Ehlers MM; Dreyer AW; Kock MM BMC Infect Dis; 2015 Nov; 15():521. PubMed ID: 26573617 [TBL] [Abstract][Full Text] [Related]
46. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
47. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii. Seifert H; Stefanik D; Olesky M; Higgins PG Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740 [TBL] [Abstract][Full Text] [Related]
48. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium. Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010 [TBL] [Abstract][Full Text] [Related]
49. A prospective multicenter study on the evaluation of antimicrobial resistance and molecular epidemiology of multidrug-resistant Acinetobacter baumannii infections in intensive care units with clinical and environmental features. Boral B; Unaldi Ö; Ergin A; Durmaz R; Eser ÖK; Ann Clin Microbiol Antimicrob; 2019 Jul; 18(1):19. PubMed ID: 31266519 [TBL] [Abstract][Full Text] [Related]
50. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Seifert H; Stefanik D; Sutcliffe JA; Higgins PG Int J Antimicrob Agents; 2018 Jan; 51(1):62-64. PubMed ID: 28705668 [TBL] [Abstract][Full Text] [Related]
51. Yang Y; Guo Y; Yin D; Zheng Y; Wu S; Zhu D; Hu F Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33139291 [TBL] [Abstract][Full Text] [Related]
52. [Evaluation of the efficacy of colistin/sulbactam combination on carbapenem-resistant Acinetobacter baumannii strains]. Çetinkol Y; Telli M; Altunçekiç Yıldırım A; Çalgın MK Mikrobiyol Bul; 2016 Jul; 50(3):460-5. PubMed ID: 27525401 [TBL] [Abstract][Full Text] [Related]
53. A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Pasteran F; Cedano J; Baez M; Albornoz E; Rapoport M; Osteria J; Montaña S; Le C; Ra G; Bonomo RA; Tolmasky ME; Adams M; Corso A; Ramirez MS Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34068158 [TBL] [Abstract][Full Text] [Related]
54. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii. Higgins PG; Stefanik D; Page MG; Hackel M; Seifert H J Antimicrob Chemother; 2012 May; 67(5):1167-9. PubMed ID: 22294643 [TBL] [Abstract][Full Text] [Related]
55. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan. Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997 [TBL] [Abstract][Full Text] [Related]
56. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018). Piérard D; Stone GG BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341 [TBL] [Abstract][Full Text] [Related]